hrp0094p2-311 | Growth and syndromes (to include Turner syndrome) | ESPE2021

Efficacy of recombinant growth hormone therapy in TRPS 1 syndrome coexisting with growth hormone deficiency.

Dyrka Kamil , Obara-Moszynska Monika , Niedziela Marek ,

Introduction: The tricho-rhino-phalangeal syndrome type 1 (TRPS 1), also known as Langer-Giedion syndrome, is an uncommon genetic disorder. This disease is characterized by short stature, cone-shaped ends of the long bones (epiphyses), and distinctive facial features linked to skeletal abnormalities since early childhood. The experience with recombinant growth hormone (rGH) therapy in TRPS 1 is relatively poor. The aim of the study is to present the results of...

hrp0098p2-362 | Late Breaking | ESPE2024

Unusual response to estrogen replacement therapy complicated by ovarian cyst in a girl with Turner syndrome

Dyrka Kamil , Kapczuk Karina , Niedziela Marek , Obara-Moszynska Monika

Background: Ovarian dysfunction is one of the most common features of Turner syndrome (TS). Oocyte apoptosis is accelerated from early fetal life, more typical for 45,X karyotype. Hypergonadotropic hypogonadism (HH) is characteristic manifestation of dysgenetic ovaries, and estrogen replacement therapy (ERT) is standard for delayed puberty. Development of ovarian follicles is largely under FSH control, and possible ovarian hyperstimulation of elevated FSH in T...

hrp0095p2-219 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

Central diabetes insipidus in children – analysis of the different clinical picture

Dyrka Kamil , Dzialach Lukasz , Derwich Katarzyna , Niedziela Marek , Obara-Moszynska Monika

Background: Central diabetes insipidus (CDI) is a rare disorder in the pediatric population. CDI may be the first symptom of a brain tumor, metastatic lesions, or granulomas. The close follow-up of patients with CDI may early detect pathologic processes, especially intracranial tumors.Methods: We present four pediatric patients diagnosed with CDI of different etiology.Pat...

hrp0097p2-17 | Growth and Syndromes | ESPE2023

Efficacy and safety of recombinant growth hormone therapy in a girl with a Loeys-Dietz syndrome

Dyrka Kamil , Tomaszewska Andzelika , Balcerzak Justyna , Aniol Zuzanna , Niedziela Marek , Obara-Moszynska Monika

The Loeys-Dietz syndrome (LDS) is a genetic heterogeneous, autosomal dominant aortic aneurysm syndrome with widespread systemic involvement. As defined by Loeys et al. (2006), the disorder is characterized by the triad of arterial tortuosity and aneurysms, hypertelorism, and bifid uvula or cleft palate. We present a 16.5-year-old girl with LDS2 caused by a mutation c.1582C>T (p.R5228C) in the TGFBR2 gene and treated with recombinant growth hormone (rGH) du...